Clinical

Dataset Information

0

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC


ABSTRACT: This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

DISEASE(S): Sarcomas,Carcinoma,Salivary Gland Cancer,Small Cell Lung Cancer,Metastatic Melanoma,Non Small Cell Lung Cancer,Urothelial Carcinoma,Lung Neoplasms,Metastatic Renal Cell Carcinoma,Ovarian Cancer,Metastatic Head And Neck Carcinoma,Pancreas Cancer,Gastric Cancer,Advanced Solid Tumor,Pancreatic Neoplasms,Salivary Gland Neoplasms,Metastatic Colorectal Cancer,Metastatic Breast Cancer,Cervical Cancer,Small Cell Lung Carcinoma,Carcinoma, Adenoid Cystic,Adenoid Cystic Carcinoma,Metastatic Prostate Cancer,Gastroesophageal Junction Adenocarcinoma,Esophageal Cancer

PROVIDER: 2320193 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-10-03 | GSE164271 | GEO
2022-01-24 | GSE194166 | GEO
2015-06-01 | E-MTAB-3448 | biostudies-arrayexpress
2016-12-23 | PXD002612 | Pride
2020-12-25 | GSE156180 | GEO
2023-01-12 | GSE189045 | GEO
2006-06-01 | GSE3438 | GEO
| PRJNA614988 | ENA
2017-03-31 | MSV000080825 | MassIVE